Topline results for Rezolute's fully enrolled open-label study in tumour HI are expected in the second half of 2026.

Gilead has touted Livdelzi's potential in patients with high ALP levels, potentially expanding the drug’s reach across the PBC indication.

Abivax has reported that the Phase III ABTECT maintenance trial of obefazimod met the primary endpoint in adults with moderately to severely active UC.

J&J’s Rybrevant and cancer vaccines are showing benefit, with detailed data presented at ASCO. Credit: Hindi Studio / Shutterstock.com During the American Society of Clinical Oncology (ASCO) meeting ...

Readouts in rare blood cancers like myelofibrosis, WM and CLL are attracting keen interest at this year’s ASCO conference.

The Phase III SUCCESSOR-2 trial (NCT05552976) enrolled patients with relapsed or refractory multiple myeloma (RRMM). Results also showed significantly improved PFS rates with Mezi ...

The data on the kappa AL amyloidosis group treated with anselamimab was presented by AstraZeneca at ASCO 2026.

Hansa Biopharma’s Idefrix (imlifidase) has seen a 90% one-year survival from GvHD in patients following a kidney transplant.

Jade Biosciences has reported positive interim data from its Phase I trial studying JADE101, an investigational anti-APRIL monoclonal antibody for IgAN.

Hepcludex is now the first and only approved treatment for HDV patients in the US, marking a significant milestone for the HDV market.

At ASCO 2026, AstraZeneca unveiled initial clinical data for AZD-3470 in relapsed/refractory classical Hodgkin lymphoma.

Readouts in hepatocellular carcinoma, as well as pancreatic, gastric and salivary gland cancer, are catching attention at ASCO 2026.